Stay updated with breaking news from Deaths Attributable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Yes! No matter your risk level, there are steps you can take to reduce your risk factors even further. Each year in April, the nation comes together to celebrate and advocate for cancer patients, survivors, and caregivers with National Cancer Control Month. Cancer is diagnosed in over 1.9 million Americans and claims the lives of
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) has approved the company’s 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name APEXXNAR. The vaccine is approved for active immunization for the prevention of invasive ...
APEXXNAR [pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)] is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible
One dose of PREVNAR 20 is recommended by ACIP for adults ages 65 and older and adults ages 19 to 64 with certain risk conditions New PREVNAR 20 one-dose guidance helps simplify long-standing adult pneumococcal recommendations Pfizer Inc. announced today that the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend PREVNAR 20 ™ for routine use to help ...
First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Helps protect against more serotypes of pneumococcal disease than any other conjugate vaccine Builds on Pfizer’s more than 20-year legacy and innovation in ...